Eduard Tiozzo1, Hannah Gardener2, Barry I Hudson2, Chuanhui Dong2, David Della-Morte2, Milita Crisby2, Ronald B Goldberg2, Mitchell S V Elkind2, Ying Kuen Cheung2, Clinton B Wright2, Ralph L Sacco2, Moise Desvarieux2, Tatjana Rundek2. 1. From the Department of Psychiatry and Behavioral Sciences, Miller School of Medicine (E.T.), Department of Neurology, Miller School of Medicine (E.T., H.G., C.D., D.D.-M., C.B.W., R.L.S., T.R.), Division of Endocrinology, Diabetes and Metabolism (B.I.H.), Diabetes Research Institute and Lipid Disorder Clinic (R.B.G.), and Department of Public Health Sciences (R.L.S.), University of Miami, FL; Department of System Medicine, University of Rome Tor Vergata, Rome, Italy (D.D.-M.); Biomarker Discovery and Advanced Technologies (BioDAT), IRCCS San Raffaele Pisana, Rome, Italy (D.D.-M.); Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden (M.C.); Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY (M.S.V.E.); Department of Biostatistics (Y.K.C.) and Department of Epidemiology (M.D.), Mailman School of Public Health, Columbia University, New York, NY; and Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS-UMR1153), Paris, France (M.D.). etiozzo@miami.edu. 2. From the Department of Psychiatry and Behavioral Sciences, Miller School of Medicine (E.T.), Department of Neurology, Miller School of Medicine (E.T., H.G., C.D., D.D.-M., C.B.W., R.L.S., T.R.), Division of Endocrinology, Diabetes and Metabolism (B.I.H.), Diabetes Research Institute and Lipid Disorder Clinic (R.B.G.), and Department of Public Health Sciences (R.L.S.), University of Miami, FL; Department of System Medicine, University of Rome Tor Vergata, Rome, Italy (D.D.-M.); Biomarker Discovery and Advanced Technologies (BioDAT), IRCCS San Raffaele Pisana, Rome, Italy (D.D.-M.); Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden (M.C.); Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY (M.S.V.E.); Department of Biostatistics (Y.K.C.) and Department of Epidemiology (M.D.), Mailman School of Public Health, Columbia University, New York, NY; and Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS-UMR1153), Paris, France (M.D.).
Abstract
BACKGROUND AND PURPOSE: Recent drug trials have challenged the high-density lipoprotein-cholesterol (HDL-C) antiatherosclerotic hypothesis, suggesting that total level of HDL-C may not be the best target for intervention. HDL-C subfractions may be better markers of vascular risk than total levels of HDL-C. The objective of this cross-sectional study was to investigate the relationship between HDL2-C and HDL3-C fractions and carotid intima-media thickness (cIMT) in the population-based Northern Manhattan Study. METHODS: We evaluated 988 stroke-free participants (mean age, 66±8 years; 60% women; 66% Hispanic, and 34% non-Hispanic) with available data on HDL-C subfractions using precipitation method and cIMT assessed by a high-resolution carotid ultrasound. The associations between HDL-C subfractions and cIMT were analyzed by multiple linear regression models. RESULTS: The mean HDL2-C was 14±8 mg/dL, HDL3-C 32±8 mg/dL, and the mean total HDL-C was 46±14 mg/dL. The mean cIMT was 0.90±0.08 mm. After controlling for demographics and vascular risk factors, HDL2-C and total HDL-C were inversely associated with cIMT (per 2 SDs, β=-0.017, P=0.001 and β=-0.012, P=0.03, respectively). The same inverse association was more pronounced among those with diabetes mellitus (per 2SDs, HDL2-C: β=-0.043, P=0.003 and HDL-C: β=-0.029, P=0.02). HDL3-C was not associated with cIMT. CONCLUSIONS: HDL2-C had greater effect on cIMT than HDL3-C in this large urban population. The effect of HDL2-C was especially pronounced among individuals with diabetes mellitus. More research is needed to determine antiatherosclerotic effects of HDL-C subfractions and their clinical relevance.
BACKGROUND AND PURPOSE: Recent drug trials have challenged the high-density lipoprotein-cholesterol (HDL-C) antiatherosclerotic hypothesis, suggesting that total level of HDL-C may not be the best target for intervention. HDL-C subfractions may be better markers of vascular risk than total levels of HDL-C. The objective of this cross-sectional study was to investigate the relationship between HDL2-C and HDL3-C fractions and carotid intima-media thickness (cIMT) in the population-based Northern Manhattan Study. METHODS: We evaluated 988 stroke-freeparticipants (mean age, 66±8 years; 60% women; 66% Hispanic, and 34% non-Hispanic) with available data on HDL-C subfractions using precipitation method and cIMT assessed by a high-resolution carotid ultrasound. The associations between HDL-C subfractions and cIMT were analyzed by multiple linear regression models. RESULTS: The mean HDL2-C was 14±8 mg/dL, HDL3-C 32±8 mg/dL, and the mean total HDL-C was 46±14 mg/dL. The mean cIMT was 0.90±0.08 mm. After controlling for demographics and vascular risk factors, HDL2-C and total HDL-C were inversely associated with cIMT (per 2 SDs, β=-0.017, P=0.001 and β=-0.012, P=0.03, respectively). The same inverse association was more pronounced among those with diabetes mellitus (per 2SDs, HDL2-C: β=-0.043, P=0.003 and HDL-C: β=-0.029, P=0.02). HDL3-C was not associated with cIMT. CONCLUSIONS:HDL2-C had greater effect on cIMT than HDL3-C in this large urban population. The effect of HDL2-C was especially pronounced among individuals with diabetes mellitus. More research is needed to determine antiatherosclerotic effects of HDL-C subfractions and their clinical relevance.
Authors: J E Buring; G T O'Connor; S Z Goldhaber; B Rosner; P N Herbert; C B Blum; J L Breslow; C H Hennekens Journal: Circulation Date: 1992-01 Impact factor: 29.690
Authors: H Robert Superko; Lakshmana Pendyala; Paul T Williams; Katherine M Momary; Spencer B King; Brenda C Garrett Journal: J Clin Lipidol Date: 2012-03-23 Impact factor: 4.766
Authors: Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora Journal: J Am Coll Cardiol Date: 2012-07-11 Impact factor: 24.094
Authors: Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu Journal: N Engl J Med Date: 2007-03-26 Impact factor: 91.245
Authors: Michiel L Bots; Frank L Visseren; Gregory W Evans; Ward A Riley; James H Revkin; Charles H Tegeler; Charles L Shear; William T Duggan; Ralph M Vicari; Diederick E Grobbee; John J Kastelein Journal: Lancet Date: 2007-07-14 Impact factor: 79.321
Authors: Diego Estrada-Luna; María Araceli Ortiz-Rodriguez; Lizett Medina-Briseño; Elizabeth Carreón-Torres; Jeannett Alejandra Izquierdo-Vega; Ashutosh Sharma; Juan Carlos Cancino-Díaz; Oscar Pérez-Méndez; Helen Belefant-Miller; Gabriel Betanzos-Cabrera Journal: Molecules Date: 2018-10-23 Impact factor: 4.411